TLR2 and TRL4 inhibition effective in treatment of polymicrobial sepsis
Monday, September 5, 2016
Short summary of Lima, C et al; Therapeutic Effects of Treatment with Anti-TLR2 and Anti-TLR4 Monoclonal Antibodies in Polymicrobial Sepsis. Full article can be found here.
Toll-like receptors (TLRs) play an important role in the recognition of exogenous and endogenous danger signals. Although signaling through TLRs is an important element of host defense, a growing body of evidence indicates that dysregulation of these receptors may also play a role in the pathogenesis of sepsis. The massive release of inflammatory mediators into the bloodstream following TLR activation is suspected to be associated with sepsis, culminating in multiple organ failure.
Sepsis-induced mice were administered with antibodies blocking TLR2 (mAb T2.5 HM1054-FS) or TLR4 45 minutes before or 3 hours after sepsis induction. The results demonstrate that blockade of TLR2 or TLR4 was successful in decreasing disease severity in sepsis models of Gram-negative and-positive bacteria. This outcome reinforces the role of TLRs in the pathogenesis of sepsis and suggest that blockade of TLR2 or TLR4 may be a useful therapeutic approach to control systemic inflammation, organ injury and lethality in polymicrobial sepsis.